Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease

NCT00001662 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT00001662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 2
Overall status
Completed
Start date
December 31, 1996
Completion date
November 30, 2005
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, dementia